TY - JOUR
T1 - The adjuvant Bordetella colonization factor A attenuates alum-induced Th2 responses and enhances Bordetella pertussis clearance from mouse lungs
AU - Jennings-Gee, Jamie
AU - Quataert, Sally
AU - Ganguly, Tridib
AU - D'Agostino, Ralph
AU - Deora, Rajendar
AU - Dubey, Purnima
N1 - Funding Information:
We thank Kacy Yount, Marisela Velasquez de Kamm, and Amy Medford for technical assistance, Steven Mizel for providing F1/V fusion protein, and Stephanie Seveau and Amy Lovett-Racke for critical review of the manuscript. We acknowledge the Flow Cytometry Shared Resource of the Comprehensive Cancer Center at WFUHS (supported in part by NIH/NCI P30 CA121291-37). This work was supported by NIAID/RPRC subcontract HHSN272201200005C (to R. Deora), NIH/NIAID 1R01AI125560-01 (to P. Dubey and R. Deora), pilot HHSN272201200005C/AI/NIAID NIH HHS/United States (to S. Quataert) and Wake Forest Innovations. Author contributions: J. Jennings-Gee conducted experiments and analyzed data, S. Quataert conducted experiments and analyzed data, T. Ganguly conducted experi ments, R. D'Agostino, Jr., conducted statistical analysis, and P. Dubey and R. Deora designed and conducted experiments, analyzed data, and wrote the paper.
Publisher Copyright:
© 2018 American Society for Microbiology.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - The reemergence of pertussis or whooping cough in several countries highlights the need for better vaccines. Acellular pertussis vaccines (aPV) contain alum as the adjuvant and elicit Th2-biased immune responses that are less effective in protecting against infection than the reactogenic whole-cell pertussis vaccines (wPV), which elicit primarily a Th1/Th17 response. An important goal for the field is to devise aPV that will induce immune responses similar to those of wPV. We show that Bordetella colonization factor A (BcfA), an outer membrane protein from Bordetella bronchiseptica, has strong adjuvant function and elicits cellular and humoral immune responses to heterologous and Bordetella pertussis antigens. Addition of BcfA to a commercial aPV resulted in greater reduction of B. pertussis numbers from the lungs than that elicited by aPV alone. The more-efficient pathogen clearance was accompanied by increased interleukin-17 (IL- 17) and reduced IL-5 and an increased ratio of IgG2/IgG1 antibodies. Thus, our results suggest that BcfA improves aPV-induced responses by modifying the alum-induced Th2- biased aPV response toward Th1/Th17. A redesigned aPV containing BcfA may allow better control of pertussis reemergence by reshaping immune responses to resemble those elicited by wPV immunization.
AB - The reemergence of pertussis or whooping cough in several countries highlights the need for better vaccines. Acellular pertussis vaccines (aPV) contain alum as the adjuvant and elicit Th2-biased immune responses that are less effective in protecting against infection than the reactogenic whole-cell pertussis vaccines (wPV), which elicit primarily a Th1/Th17 response. An important goal for the field is to devise aPV that will induce immune responses similar to those of wPV. We show that Bordetella colonization factor A (BcfA), an outer membrane protein from Bordetella bronchiseptica, has strong adjuvant function and elicits cellular and humoral immune responses to heterologous and Bordetella pertussis antigens. Addition of BcfA to a commercial aPV resulted in greater reduction of B. pertussis numbers from the lungs than that elicited by aPV alone. The more-efficient pathogen clearance was accompanied by increased interleukin-17 (IL- 17) and reduced IL-5 and an increased ratio of IgG2/IgG1 antibodies. Thus, our results suggest that BcfA improves aPV-induced responses by modifying the alum-induced Th2- biased aPV response toward Th1/Th17. A redesigned aPV containing BcfA may allow better control of pertussis reemergence by reshaping immune responses to resemble those elicited by wPV immunization.
KW - Acellular pertussis vaccines
KW - Adjuvant
KW - Bordetella pertussis
UR - https://www.scopus.com/pages/publications/85047387888
U2 - 10.1128/IAI.00935-17
DO - 10.1128/IAI.00935-17
M3 - Article
C2 - 29531137
AN - SCOPUS:85047387888
SN - 0019-9567
VL - 86
JO - Infection and immunity
JF - Infection and immunity
IS - 6
M1 - e00935-17
ER -